Low Levels of Low-Density Lipoprotein Cholesterol and Blood Pressure and Progression of Coronary Atherosclerosis

被引:59
作者
Chhatriwalla, Adnan K. [1 ]
Nicholls, Stephen J. [1 ,2 ,4 ]
Wang, Thomas H. [1 ]
Wolski, Kathy [1 ]
Sipahi, Ilke [1 ]
Crowe, Tim [1 ]
Schoenhagen, Paul [1 ,3 ]
Kapadia, Samir [1 ]
Tuzcu, E. Murat [1 ]
Nissen, Steven E. [1 ]
机构
[1] Cleveland Clin, Dept Cardiovasc Med, Cleveland, OH 44195 USA
[2] Cleveland Clin, Dept Cell Biol, Cleveland, OH 44195 USA
[3] Cleveland Clin, Dept Radiol, Cleveland, OH 44195 USA
[4] Cleveland Clin, Ctr Cardiovasc Diagnost & Prevent, Cleveland, OH 44195 USA
关键词
coronary artery disease; atherosclerosis; cholesterol; LDL-C; hypertension; blood pressure; intravascular ultrasound; THERAPY; HYPERTENSION; DISEASE; INHIBITION; PREVALENCE; PREVENTION; REGRESSION; TARGETS; ADULTS;
D O I
10.1016/j.jacc.2008.09.065
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives We investigated coronary atheroma progression in patients with low levels of low-density lipoprotein cholesterol (LDL-C) and systolic blood pressure (SBP). Background Low LDL-C and SBP beneficially impact coronary atherosclerosis. However, the association between intensive control of both risk factors and coronary plaque progression remains unclear. Methods Changes in atheroma burden monitored by intravascular ultrasound were studied in 3,437 patients with coronary artery disease (CAD) who were stratified according to on-treatment LDL-C and SBP. Results Patients with very low LDL-C (<= 70 mg/dl) and normal SBP (<= 120 mm Hg) had less progression in percent atheroma volume (PAV) (p < 0.001) and total atheroma volume (TAV) (p < 0.001), more frequent plaque regression (p = 0.01), and less frequent plaque progression (p < 0.001). In patients with SBP <= 120 mm Hg, very low LDL-C was associated with less progression of PAV (+ 0.30%, 95% confidence interval [CI]:-0.17% to 0.77% vs. + 0.61%, 95% CI: 0.17% to 1.05%, p = 0.01) and TAV (-3.9 mm(3), 95% CI:-7.24 to-0.63 mm(3) vs.-1.2 mm(3), 95% CI:-4.31 to 1.92 mm(3), p < 0.001). In patients with LDL-C <= 70 mg/dl, normal SBP was not associated with less progression of PAV (+ 0.51%, 95% CI: 0.04% to 0.99% vs. + 0.61%, 95% CI: 0.17% to 1.05%, p = 0.159) or TAV (-2.3 mm(3), 95% CI:-5.59 to 1.05 mm(3) vs.-1.2 mm(3), 95% CI:-4.31 to 1.92 mm3, p = 0.617). Conclusions Very low LDL-C and normal SBP are associated with the slowest progression of coronary atherosclerosis. Although a greater beneficial association is observed in patients with very low LDL-C, these findings suggest the need for intensive control of global risk in patients with CAD. (J Am Coll Cardiol 2009; 53: 1110-5) (C) 2009 by the American College of Cardiology Foundation
引用
收藏
页码:1110 / 1115
页数:6
相关论文
共 24 条
[1]   CORONARY ANGIOGRAPHIC CHANGES WITH LOVASTATIN THERAPY - THE MONITORED ATHEROSCLEROSIS REGRESSION STUDY (MARS) [J].
BLANKENHORN, DH ;
AZEN, SP ;
KRAMSCH, DM ;
MACK, WJ ;
CASHINHEMPHILL, L ;
HODIS, HN ;
DEBOER, LWV ;
MAHRER, PR ;
MASTELLER, MJ ;
VAILAS, LI ;
ALAUPOVIC, P ;
HIRSCH, LJ .
ANNALS OF INTERNAL MEDICINE, 1993, 119 (10) :969-976
[2]   Intensive versus moderate lipid lowering with statins after acute coronary syndromes [J].
Cannon, CP ;
Braunwald, E ;
McCabe, CH ;
Rader, DJ ;
Rouleau, JL ;
Belder, R ;
Joyal, SV ;
Hill, KA ;
Pfeffer, MA ;
Skene, AM .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (15) :1495-1504
[3]   Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure [J].
Chobanian, AV ;
Bakris, GL ;
Black, HR ;
Cushman, WC ;
Green, LA ;
Izzo, JL ;
Jones, DW ;
Materson, BJ ;
Oparil, S ;
Wright, JT ;
Roccella, EJ .
HYPERTENSION, 2003, 42 (06) :1206-1252
[4]   Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines [J].
Grundy, SM ;
Cleeman, JI ;
Merz, CNB ;
Brewer, HB ;
Clark, LT ;
Hunninghake, DB ;
Pasternak, RC ;
Smith, SC ;
Stone, NJ .
CIRCULATION, 2004, 110 (02) :227-239
[5]   Effect of lower targets for blood pressure and LDL cholesterol on atherosclerosis in diabetes - The SANDS randomized trial [J].
Howard, Barbara V. ;
Roman, Mary J. ;
Devereux, Richard B. ;
Fleg, Jerome L. ;
Galloway, James M. ;
Henderson, Jeffrey A. ;
Howard, Wm. James ;
Lee, Elisa T. ;
Mete, Mihriye ;
Poolaw, Bryce ;
Ratner, Robert E. ;
Russell, Marie ;
Silverman, Angela ;
Stylianou, Mario ;
Umans, Jason G. ;
Wang, Wenyu ;
Weir, Matthew R. ;
Weissman, Neil J. ;
Wilson, Charlton ;
Yeh, Fawn ;
Zhu, Jianhui .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2008, 299 (14) :1678-1689
[6]   Effect of combined treatment with an angiotensin II receptor antagonist and an HMG-CoA reductase inhibitor on atherosclerosis in genetically hyperlipidemic rabbits [J].
Kato, M ;
Sada, T ;
Mizuno, M ;
Kitayama, K ;
Inaba, T ;
Koike, H .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2005, 46 (04) :556-562
[7]   Worldwide prevalence of hypertension: a systematic review [J].
Kearney, PM ;
Whelton, M ;
Reynolds, K ;
Whelton, PK ;
He, J .
JOURNAL OF HYPERTENSION, 2004, 22 (01) :11-19
[8]  
Lewington S, 2002, LANCET, V360, P1903, DOI 10.1016/S0140-6736(02)11911-8
[9]   Hypertension in adults across the age spectrum - Current outcomes and control in the community [J].
Lloyd-Jones, DM ;
Evans, JC ;
Levy, D .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2005, 294 (04) :466-472
[10]   Effect of ACAT inhibition on the progression of coronary atherosclerosis [J].
Nissen, SE ;
Tuzcu, EM ;
Brewer, HB ;
Sipahi, I ;
Nicholls, SJ ;
Ganz, P ;
Schoenhagen, P ;
Waters, DD ;
Pepine, CJ ;
Crowe, TD ;
Davidson, MH ;
Deanfield, JE ;
Wisniewski, LM ;
Hanyok, JJ ;
Kassalow, LM .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (12) :1253-1263